Weight & Metabolic · Investigational · Phase 3
Retatrutide
Triple‑agonist · GLP‑1 / GIP / Glucagon · Weight · Metabolic
The investigational triple agonist at GIP, GLP-1 and glucagon, currently in phase-3 study.
- Form
- 30 mg / 60 mg — pre-reconstituted in the Cellvéra injector
- Oversight
- Licensed clinician, included
- 30 mg pen
- R4 599 / protocol
- 60 mg pen
- R6 647 / protocol
Opens a private email to our concierge · nothing is charged
Checkout begins your confidential medical intake. Retatrutide is dispensed only if a licensed clinician prescribes it after reviewing your intake — nothing is charged until your provider approves.
Pathway
An investigational "triple agonist" developed by Eli Lilly — the next-generation relative of the GLP-1 weight-loss medicines, acting on three metabolic receptors at once rather than one or two. Not an approved medicine.
Mechanism
It mimics two natural gut hormones, GIP and GLP-1, which together reduce appetite, slow stomach emptying and improve insulin release. It then adds a third action on the glucagon receptor, which increases the rate at which the body burns energy — eating less and burning more is what sets it apart from earlier drugs in the class.
Studied for
- Substantial body-weight reduction in people with obesity
- Blood-sugar control in type 2 diabetes
- Fatty liver disease (MASH/NAFLD)
- Obstructive sleep apnoea and obesity-related knee osteoarthritis
Areas of research interest — not promised outcomes.
Where the evidence stands
In a 48-week Phase 2 trial published in the New England Journal of Medicine, the highest dose produced an average body-weight reduction of roughly 24% — among the largest figures ever reported for an obesity drug. The Phase 3 programme is currently underway.
Typical protocol
Titrated from a conservative starting dose upward over 24+ weeks, exactly per your supervising clinician — reported effects are mostly gastrointestinal and dose-related.
Contraindications & cautions
Investigational use only — not approved by any major regulator. Personal/family history of medullary thyroid carcinoma. MEN-2 syndrome. Pancreatitis history. Pregnancy or breastfeeding. Dose-related heart-rate increases have been observed.
Prescribed only after evaluation by your supervising provider, based on your history and bloodwork.